Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
10.1016/s0928-4257(97)89474-0 120 SikiricP.SeiwerthS.GrabarevicZ.RucmanR.PetekM.JagicV.et al (1997a)
GLP-1 also seem to act on the reward and satiety centers of the brain (more research is being done on exactly what mechanisms)
But based on the pharmacological profiles of both, most providers consider this a low-risk combination for the majority of patients
which Pfizer claims conspired with Metsera and Novo Nordisk in furtherance of these anticompetitive activities. Pfizer claims the defendants are in violation of the Clayton Act, an act aimed at preventing anticompetitive practices and the Sherman Act, which outlaws monopolistic business practices
[Thus,] the scope of these drugs and the potential benefit of these drugs is likely to be much broader than what was originally described.
